Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
ChinaBio® Investor Forum–Jinan Selects Two “Most Promising” Companies
publication date: Jul 21, 2011
|
author/source: Richard Daverman, PhD
The ChinaBio® Investor Forum–Jinan chose two early stage life science companies as the “Most Promising” of the 17 presenting companies at the recently held conference. Cardeus Pharmaceuticals was selected in the pharmaceutical category, and Beijing UniMedex was named in the devices and services group.
The ChinaBio event brought together more than 180 attendees, including international VCs and investors from China, the US, and Japan. A panel of VCs and pharma executives selected the two companies for the "Most Promising" honor based on their especially compelling business plans.
Cardeus Pharmaceuticals, Inc. has recently completed a license agreement with Astellas Pharma for the development of three promising compounds, adding new intellectual property to expand the use of these compounds. Two of these compounds have been in Phase II clinical studies and the third is IND-enabled. Cardeus will create a subsidiary company in China to take the lead in one therapeutic area while the US parent company focuses its resources on a different therapeutic area. Cardeus plans to develop these compounds for the US, Asian, and European markets.
UniMedex is a wholly owned subsidiary of Suzhou Da Wei Biopharmaceutical. It specializes in the research, design, manufacture, and sale of the Intelligent Urinary Control System (IUCS) for the treatment of patients with neurogenic bladders. Current treatment devices, which use Foley catheters and urine bags, often cause urine reflux into the kidneys, which results in hydronephrosis and uremia. IUCS has developed a unique pressure sensing technology system, which will monitor urine flow, activate a voiding mechanism, and prevent urine reflux.
This event was the eleventh Investor Forum in China organized by ChinaBio® LLC in less than four years. ChinaBio has helped raise over $450 million in government and VC funding for emerging life science companies through these events.
On September 21-22, ChinaBio will hold its fourth annual BioBay Investor Forum in Suzhou at the Dushu Lake Hotel Suzhou. Held in conjunction with BioBay, one of the fastest growing life science parks in China, this event is expected to attract over 250 attendees. (See website for more information.)
The ChinaBio event brought together more than 180 attendees, including international VCs and investors from China, the US, and Japan. A panel of VCs and pharma executives selected the two companies for the "Most Promising" honor based on their especially compelling business plans.
Cardeus Pharmaceuticals, Inc. has recently completed a license agreement with Astellas Pharma for the development of three promising compounds, adding new intellectual property to expand the use of these compounds. Two of these compounds have been in Phase II clinical studies and the third is IND-enabled. Cardeus will create a subsidiary company in China to take the lead in one therapeutic area while the US parent company focuses its resources on a different therapeutic area. Cardeus plans to develop these compounds for the US, Asian, and European markets.
UniMedex is a wholly owned subsidiary of Suzhou Da Wei Biopharmaceutical. It specializes in the research, design, manufacture, and sale of the Intelligent Urinary Control System (IUCS) for the treatment of patients with neurogenic bladders. Current treatment devices, which use Foley catheters and urine bags, often cause urine reflux into the kidneys, which results in hydronephrosis and uremia. IUCS has developed a unique pressure sensing technology system, which will monitor urine flow, activate a voiding mechanism, and prevent urine reflux.
This event was the eleventh Investor Forum in China organized by ChinaBio® LLC in less than four years. ChinaBio has helped raise over $450 million in government and VC funding for emerging life science companies through these events.
On September 21-22, ChinaBio will hold its fourth annual BioBay Investor Forum in Suzhou at the Dushu Lake Hotel Suzhou. Held in conjunction with BioBay, one of the fastest growing life science parks in China, this event is expected to attract over 250 attendees. (See website for more information.)
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
